PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2018 | 8 | 4 | 114-119
Article title

Hypoalbuminemia as a relapse risk factor after high dose chemotherapy and autologous stem cell transplantation in patients with Hodgkin’s lymphoma

Content
Title variants
Languages of publication
EN
Abstracts
EN
Assessing the risk factors according to EORTC (European Organization of Research and Treatment of Cancer) or HD IPS (Hodgkin’s lymphoma International Prognostic Score) is crucial for choosing the adequate I line therapy in Hodgkin’s lymphoma patients. However, none of those scales predicts the efficacy of autologous stem cell transplant (ASCT) in relapsing/refractory (R/R) patients. Progression- free survival (PFS) after ASCT corelates with the response to salvage regimens. Thirty-nine Hodgkin’s lymphoma patients transplanted at Jagiellonian University Department of Hematology with a follow-up exceeding 5 years were analyzed. Despite long time periods since the diagnosis, initial serum albumin levels seem to correlate with progression after autologous stem cell transplant and indicate high probability of relapse within 5 months following the procedure with favorable test characteristics.
Discipline
Publisher
Journal
Year
Volume
8
Issue
4
Pages
114-119
Physical description
Contributors
  • Department of Allergy and Immunology, Jagiellonian University Medical College, Cracow, Poland
  • Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
  • Department of Anatomy, Jagiellonian University Medical College, Cracow, Poland
author
  • Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland
  • Department of Anatomy, Jagiellonian University Medical College, Cracow, Poland
  • Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
References
  • 1. Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol 2015; 26(10): 2026-2033. DOI: 10.1093/annonc/mdv256.
  • 2. Klimm B, Goergen H, Fuchs M et al. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions. Ann Oncol 2013; 24(12): 3070-3076. DOI: 10.1093/annonc/mdt413.
  • 3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339(21): 1506-1514. DOI: 10.1056/NEJM199811193392104.
  • 4. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003; 348(24): 2386-2395. DOI: 10.1056/NEJMoa022473.
  • 5. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36(1): 252-259.
  • 6. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586. DOI: 10.1200/ JCO.2006.09.2403.
  • 7. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W et al. Outcome and prognostic factors in advanced Hodgkin’s disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 2004; 15(8): 1222-1230. DOI: 10.1093/annonc/mdh304.
  • 8. Moskowitz CH, Matasar MJ, Zelenetz AD et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119(7): 1665-1670. DOI: 10.1182/blood-2011-10-388058.
  • 9. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood 1993; 81(5): 1137-1145.
  • 10. Gaiolla RD, Domingues MA, Niero-Melo L et al. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med 2011; 135(4): 483-489. DOI: 10.1043/2010-0060-OA.1.
  • 11. Bohlen H, Kessler M, Sextro M et al. Poor clinical outcome of patients with Hodgkin’s disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin’s disease. Ann Hematol 2000; 79(3): 110-113.
  • 12. Czyz J, Hellmann A, Dziadziuszko R et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin’s disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002; 30(1): 29-34. DOI: 10.1038/sj.bmt.1703590.
  • 13. Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007; 92(1): 35-41.
  • 14. Santoro A, Mazza R, Pulsoni A et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol 2016; 34(27): 3293-3299. DOI: 10.1200/JCO.2016.66.4466.
  • 15. Chen R, Gopal AK, Smith SE et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128(12): 1562-1566. DOI: 10.1182/blood-2016-02-699850.
  • 16. O’Connor OA, Lue JK, Sawas A et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol 2018; 19(2): 257-266. DOI: 10.1016/S1470-2045(17)30912-9.
  • 17. LaCasce AS, Bociek RG, Sawas A et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018; 132(1): 40-48. DOI: 10.1182/blood-2017-11-815183.
  • 18. Broccoli A, Zinzani PL. The role of transplantation in Hodgkin lymphoma. Br J Haematol 2018. DOI: 10.1111/bjh.15639.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-764dafd4-3bef-4c95-b2e8-ef846d151e83
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.